Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB – Get Free Report) insider Thomas Gad sold 10,810 shares of Y-mAbs Therapeutics stock in a transaction that occurred on Friday, March 7th. The stock was sold at an average price of $5.23, for a total value of $56,536.30. Following the transaction, the insider now owns 202,721 shares of the company’s stock, valued at $1,060,230.83. This represents a 5.06 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.
Y-mAbs Therapeutics Price Performance
Shares of YMAB stock opened at $4.73 on Friday. The firm has a market capitalization of $213.88 million, a P/E ratio of -8.76 and a beta of 0.65. Y-mAbs Therapeutics, Inc. has a 12 month low of $4.25 and a 12 month high of $17.78. The company’s fifty day moving average price is $6.11 and its two-hundred day moving average price is $10.28.
Y-mAbs Therapeutics (NASDAQ:YMAB – Get Free Report) last released its quarterly earnings data on Tuesday, March 4th. The company reported ($0.15) earnings per share for the quarter, missing the consensus estimate of ($0.13) by ($0.02). Y-mAbs Therapeutics had a negative return on equity of 24.61% and a negative net margin of 28.22%. The business had revenue of $26.50 million for the quarter, compared to analyst estimates of $26.70 million. During the same quarter last year, the company earned ($0.02) EPS. On average, sell-side analysts anticipate that Y-mAbs Therapeutics, Inc. will post -0.65 EPS for the current year.
Institutional Inflows and Outflows
Analysts Set New Price Targets
YMAB has been the subject of several research reports. Wedbush restated an “outperform” rating and set a $23.00 price objective on shares of Y-mAbs Therapeutics in a research report on Monday, March 3rd. HC Wainwright reiterated a “buy” rating and issued a $22.00 price target on shares of Y-mAbs Therapeutics in a report on Monday, January 13th. Brookline Capital Management assumed coverage on Y-mAbs Therapeutics in a report on Thursday, December 5th. They issued a “buy” rating and a $17.00 price target for the company. Bank of America cut their price target on Y-mAbs Therapeutics from $14.00 to $12.00 and set a “neutral” rating for the company in a report on Wednesday, March 5th. Finally, Morgan Stanley cut their price target on Y-mAbs Therapeutics from $11.00 to $7.00 and set an “underweight” rating for the company in a report on Wednesday, March 5th. One research analyst has rated the stock with a sell rating, one has given a hold rating, seven have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average price target of $19.30.
Check Out Our Latest Stock Report on Y-mAbs Therapeutics
About Y-mAbs Therapeutics
Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.
Further Reading
- Five stocks we like better than Y-mAbs Therapeutics
- How is Compound Interest Calculated?
- 3 Undervalued Stocks You Can Buy at a Discount Now
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- AMD Stock: Can the PC Refresh Cycle Spark a Rally?
- What Are Dividends? Buy the Best Dividend Stocks
- Micron Stock Spikes 7%—3 Key Catalysts Behind the Move
Receive News & Ratings for Y-mAbs Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Y-mAbs Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.